Whitehawk Therapeutics CEO Sells $93,465 in Stock as Company Advances HWK-007 Program
Whitehawk Therapeutics Chief Executive Officer David James Lennon sold 26,858 shares on April 2, 2026, in a broker-assisted transaction to cover tax obligations tied to restricted stock units. The sale, executed at $3.48 per share for a total of $93,465, comes after Lennon exercised options and received additional shares on April 1, 2026. Separatel…